Literature DB >> 8782457

Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice.

M F Neurath1, S Pettersson, K H Meyer zum Büschenfelde, W Strober.   

Abstract

Chronic intestinal inflammation induced by 2,4,6,-trinitrobenzene sulfonic acid (TNBS) is characterized by a transmural granulomatous colitis that mimics some characteristics of human Crohn's disease. Here, we show that the transcription factor NF-kappa B p65 was strongly activated in TNBS-induced colitis and in colitis of interleukin-10-deficient mice. Local administration of p65 antisense phosphorothioate oligonucleotides abrogated clinical and histological signs of colitis and was more effective in treating TNBS-induced colitis than single or daily administration of glucocorticoids. The data provide direct evidence for the central importance of p65 in chronic intestinal inflammation and suggest a potential therapeutic utility of p65 antisense oligonucleotides as a novel molecular approach for the treatment of patients with Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8782457     DOI: 10.1038/nm0996-998

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  219 in total

Review 1.  Management of Crohn's disease.

Authors:  D S Rampton
Journal:  BMJ       Date:  1999-12-04

Review 2.  NF-kappaB: a key role in inflammatory diseases.

Authors:  P P Tak; G S Firestein
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

Review 3.  Series introduction: the transcription factor NF-kappaB and human disease.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

4.  Activation of nuclear factor kappaB as a target for anti-inflammatory therapy.

Authors:  S Schreiber
Journal:  Gut       Date:  1999-03       Impact factor: 23.059

5.  New treatments for inflammatory bowel disease.

Authors:  David S Rampton; D Phil
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

Review 6.  Small therapeutic molecules for the treatment of inflammatory bowel disease.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 7.  Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention.

Authors:  J Panés; M Perry; D N Granger
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

8.  Styrene maleic acid encapsulated raloxifene micelles for management of inflammatory bowel disease.

Authors:  Khaled Greish; Safa Taha; Anfal Jasim; Sara Abd Elghany; Ameera Sultan; Ali AlKhateeb; Manal Othman; Fang Jun; Sebastien Taurin; Moiz Bakhiet
Journal:  Clin Transl Med       Date:  2017-08-03

9.  ICAM-1 and VCAM-1 antisense oligonucleotides attenuate in vivo leucocyte adherence and inflammation in rat inflammatory bowel disease.

Authors:  E Rijcken; C F Krieglstein; C Anthoni; M G Laukoetter; R Mennigen; H U Spiegel; N Senninger; C F Bennett; G Schuermann
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 10.  Genetically engineered mouse models for studying inflammatory bowel disease.

Authors:  Atsushi Mizoguchi; Takahito Takeuchi; Hidetomo Himuro; Toshiyuki Okada; Emiko Mizoguchi
Journal:  J Pathol       Date:  2015-11-14       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.